The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma

The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma

Abstract The nongenetic mechanisms required to control tumor phenotypic plasticity and shape drug‐resistance remain unclear. We show here that the Aryl hydrocarbon Receptor (AhR) transcription factor directly regulates the gene expression program associated with the acquisition of resistance to BRAF...

Full description

Bibliographic Details
Main Authors: Anaïs Paris, Nina Tardif, Francesca M Baietti, Cyrille Berra, Héloïse M Leclair, Eleonora Leucci, Marie‐Dominique Galibert, Sébastien Corre
Format: Article
Language:English
Published: Springer Nature 2022-12-01
Series:EMBO Molecular Medicine
Subjects:
BRAFi resistance
cell plasticity
expression
melanoma
Online Access:https://doi.org/10.15252/emmm.202215677

Similar Items

Similar Items